ImmunoVaccine Completes Scale-Up of VacciMax

December 13, 2007
BioPharm International Editors

ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), has successfully scaled up the manufacturing process for its vaccine platform, VacciMax.

ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), has successfully scaled up the manufacturing process for its vaccine platform, VacciMax. This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications. The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. The results show that IVT’s vaccine delivery platform can be produced on a commercial scale.

VacciMax is a vaccine-enhancement platform comprising a special emulsion of liposomes, antigens, adjuvants, and oil. The ability to scale-up, under GMP, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.

ImmunoVaccine release

Related Content:

News